VBL Therapeutics to Present at Upcoming Conferences in April
March 25 2019 - 8:00AM
VBL Therapeutics (Nasdaq: VBLT), today announces that the Company
will present data on its Phase 3 drug candidate VB-111, at the 2019
American Association for Cancer Research (AACR) Annual Meeting, to
be held March 29 - April 3, 2019 at Georgia World Congress Center
in Atlanta, Georgia. VB-111 is a first-in-class, targeted
anti-cancer gene-therapy biologic with broad potential to treat a
wide range of solid tumors. In addition, the company will
provide a corporate overview at the H.C. Wainwright Global Life
Sciences Conference to be held April 7 - 9, 2019 at the Grosvenor
House, a JW Marriott Hotel in London, UK.
|
The
AACR Annual Meeting - Presentation Details: |
Title: |
Ofranergene Obadenovec
(VB-111), an anti-cancer gene therapy, induces immunologic
responses in solid tumors transforming 'cold' tumors to 'hot'
tumors |
Session
Category: |
Immunology |
Session
Title: |
Immunomodulators and
Response to Therapy |
Date: |
Wednesday Apr 3, 2019 |
Time: |
8:00 AM - 12:00 PM Eastern
Time |
Session
Location: |
Exhibit Hall B, Poster
Section 24 |
Poster
Board Number: |
2 |
Abstract
Number: |
4979 |
|
|
HCW Global Life Sciences Conference - Presentation
Details:
Date: Monday, April 8Time:
15:40 – 16:00 BST
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a
clinical stage biopharmaceutical company focused on the discovery,
development and commercialization of first-in-class treatments for
cancer. The Company’s lead oncology product candidate, ofranergene
obadenovec (VB-111), is a first-in-class, targeted anti-cancer
gene-therapy agent that is positioned to treat a wide range of
solid tumors. It is conveniently administered as an IV infusion
once every two months. It has been observed to be well-tolerated in
>300 cancer patients and demonstrated efficacy signals in an
“all comers” Phase 1 trial as well as in three tumor-specific Phase
2 studies. Ofranergene obadenovec is currently being studied in a
potential registration trial for platinum-resistant ovarian
cancer.
Forward Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical fact are
forward-looking statements, which are often indicated by terms such
as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,”
“intend,” “look forward to,” “may,” “plan,” “potential,” “predict,”
“project,” “should,” “will,” “would” and similar expressions. These
forward-looking statements include, but are not limited to,
statements regarding our programs, including VB-111, including
their clinical development, such as the timing thereof, therapeutic
potential and clinical results, and the scope and protection of our
intellectual property rights. These forward-looking statements are
not promises or guarantees and involve substantial risks and
uncertainties. Among the factors that could cause actual results to
differ materially from those described or projected herein include
uncertainties associated generally with research and development,
clinical trials and related regulatory reviews and approvals, the
risk that historical clinical trial results may not be predictive
of future trial results, and that we may not realize the expected
benefits of our intellectual property protection. A further list
and description of these risks, uncertainties and other risks can
be found in the Company’s regulatory filings with the U.S.
Securities and Exchange Commission, including in our annual report
on Form 20-F for the year ended December 31, 2017, and subsequent
filings with the SEC. Existing and prospective investors are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. VBL
Therapeutics undertakes no obligation to update or revise the
information contained in this press release, whether as a result of
new information, future events or circumstances or otherwise.
INVESTOR CONTACT:Michael RiceLifeSci Advisors,
LLC(646) 597-6979
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Apr 2023 to Apr 2024